281 related articles for article (PubMed ID: 35211790)
1. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
2. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
3. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
[TBL] [Abstract][Full Text] [Related]
4. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
5. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
6. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
[TBL] [Abstract][Full Text] [Related]
7. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
[TBL] [Abstract][Full Text] [Related]
9. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
11. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
[TBL] [Abstract][Full Text] [Related]
12. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study.
Mindler GT; Stauffer A; Kranzl A; Penzkofer S; Ganger R; Radler C; Haeusler G; Raimann A
Front Endocrinol (Lausanne); 2022; 13():866170. PubMed ID: 35399930
[TBL] [Abstract][Full Text] [Related]
13. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone.
Ertl DA; Le Lorier J; Gleiss A; Trabado S; Bensignor C; Audrain C; Zhukouskaya V; Coutant R; Berkenou J; Rothenbuhler A; Haeusler G; Linglart A
Orphanet J Rare Dis; 2022 Nov; 17(1):412. PubMed ID: 36371259
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
[TBL] [Abstract][Full Text] [Related]
15. Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy.
Brener R; Zeitlin L; Lebenthal Y; Brener A
Front Endocrinol (Lausanne); 2022; 13():947814. PubMed ID: 36051396
[TBL] [Abstract][Full Text] [Related]
16. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
Filler G; Tremblay O; Chen E; Huang SSH; Stein R
Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
[TBL] [Abstract][Full Text] [Related]
17. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
[TBL] [Abstract][Full Text] [Related]
18. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
[TBL] [Abstract][Full Text] [Related]
19. Burosumab: Current status and future prospects.
Goyal A; Tandon N
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
[TBL] [Abstract][Full Text] [Related]
20. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
